The biotech industry said a 158-page report published by the U.S. government on genetically engineered salmon would move the technology closer to the market. The Food and Drug Administration last week published a draft report on so-called AquAdvantage salmon that indicated they were safe to eat and will not result in significant effects on the environment.
David Edwards, director of animal biotechnology for the Biotechnology Industry Organization, told the Los Angeles Times that it was good for the fish looking ahead and reveals that the Obama administration is ready to look ahead on these technologies and allow the United States to be the leader that they should be. The biotech industry predicts AquAdvantage salmon is likely to re-energize the potentially profitable GMO research industry.[article_detail_ad_1]
Stocks belonging to the U.S. biotech industry were down 0.11% on Monday. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is quickly heading close to February 2013 commercial launch of Belviq and its partner Eisai’s seems to be prepared to hit the ground running. The ARNA stock, as of last close, traded 366.31% up from its 52 week low and was -35.41% behind its 52 week high. Its latest closing price was 20.74% above the SMA200 while the distance from SMA 50 and SMA 20 was -0.70% and -2.99% respectively. The stock has a 6-month performance of -11.74%.
Celsion Corporation (NASDAQ:CLSN) jumped more than 12% before Christmas with share price, as of the latest close, up 419.02% compared with the 52 week low and was -4.51% below the 52 week high. The stock’s latest closing price was up +121.41% from the average-price of 200 days while it kept its distance from the SMA 50 at +39.59% and +9.42% compared with the SMA 20. Its six-month period performance stands up at 202.14%
On the flip side, Oncothyreon Inc (USA)(NASDAQ:ONTY)’s latest closing price was -58.18% down from an average-price of 200 days while it maintained a distance from the SMA 50 at -59.03% and -53.89% compared with the SMA 20. The stock was up 10.53% from the 52 week low and was -79.52% below the 52 week high. It has shown a downtrend of -75.89% in the same period with a monthly performance of -60.21% and 3-month performance down -69.32%.
Hemispherx BioPharma, Inc (AMEX:HEB) was down after the Rosen Law Firm filed a securities fraud class action against the company for issuing false and misleading information about its lead drug candidate Ampligen. As of last close, HEB was 43.16% up from the 52 week low and was -75.27% below the 52 week high.
Its latest closing price was -45.40% down from an average-price of 200 days after while it kept its distance from the SMA 50 at -61.37% and -58.94% compared with the SMA 20. The 6-month performance of this stock stands at -9.33% with a fall of -72.80% in the last three months and +29.52% in the previous twelve months.